Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 27, Issue 11, 2009, Pages 1836-1843

  Gridelli, Cesare ^a   Maio, Massimo Di ^a   Chiodini, Paolo ^a   Georgoulias, Vassilis ^a   Hatzidaki, Dora ^a   Takeda, Koji ^a   Wachters, Floris M ^a   Gebbia, Vittorio ^a   Smit, Egbert F ^a   Morabito, Alessandro ^a   Gallo, Ciro ^a   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 64649091718     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.5844     Document Type: Article

References (21)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
2. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
3. Ettinger DS, Bepler G, Bueno R, et al: Non- small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:548-582, 2006
4. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2085-2103, 2000
5. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorel- bine or ifosfamide in patients with non-small cell lung cancer previously treated with platinum- containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
6. Di Maio M, Perrone F, Chiodini P, et al: Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25:1377-1382, 2007
7. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
8. Delbaldo C, Michiels S, Syz N, et al: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 292:470-484, 2004
9. Takeda K, Negoro S, Tamura T, et al: Phase III trail of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: Results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol [Epub ahead of print; January 22, 2009]
10. Georgoulias V, Kouroussis C, Agelidou A, et al: Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: A multicentre, randomised, phase II study. Br J Cancer 91:482-488, 2004
11. Georgoulias V, Agelidou A, Syrigos K, et al: Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study. Br J Cancer 93:763-769, 2005
12. Wachters FM, Groen HJ, Biesma B, et al: A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non- small-cell lung cancer who failed first-line treatment. Br J Cancer 92:15-20, 2005
13. Pectasides D, Pectasides M, Farmakis D, et al: Comparison of docetaxel and docetaxel- irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial. Ann Oncol 16:294-299, 2005
14. Gebbia V, Gridelli C, Verusio C, et al: Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non- small-cell lung cancer patients: The DISTAL-2 randomized trial. Lung Cancer 63:251-258, 2009
15. Smit EF, Groen HJ, Smit HJ, et al: A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)- NVALT 7. J Clin Oncol 26: 436s, 2008 (suppl; abstr 8050)
16. Pignon JP, Hill C: Meta-analysis of randomised clinical trials in oncology. Lancet Oncol 2:475-482, 2001
17. Liddle J, Williamson M, Irwig L: Method for Evaluating Research and Guideline Evidence. Sydney, Australia, NSW Health Department, 1996
18. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
19. Smith CT, Williamson PR, Marson AG: Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 24:1307-1319, 2005
20. Reis IM, Hirji KF, Afifi AA: Exact and asymptotic tests for homogeneity in several2x2tables. Stat Med 18:893-906, 1999
21. Johnson KR, Ringland C, Stokes BJ, et al: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 7:741-746, 2006